NEW YORK (GenomeWeb News) – Citing concerns over the legal environment surrounding Myriad Genetics' BRACAnalysis test, Credit Suisse today downgraded the Salt Lake City-based firm's stock to Underperform from Neutral.

Separately, Piper Jaffray also sounded uncertainty over the future of the test and lowered Myriad's price target but maintained an Overweight rating on the company's stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.